Improving the global management of the neurogenic bladder patient: part II.Future treatment strategies

Abstract

A wide range of new treatments have been investigated for the management of overactive bladder; few, however, have been evaluated extensively in neurogenic urinary incontinence. Further studies are required to determine the optimal dosing regimes and formulations for individual sub-populations of neurogenic bladder patients and to determine the cost-effectiveness of these interventions. With the current experience available, two treatment algorithms for a subset of patients with neurological disease have also been proposed, which suggest at which stage of management and in which patients individual therapies for neurogenic urinary incontinence could be used.

Biomaterials in urinary incontinence and treatment of their complications

“…[41] BTX is produced by the spore-forming bacterium Clostridium botulinum , which is an obligate anaerobe. There are seven distinct types of toxin (labeled A-G) which have been isolated, however, only types A and B have been widely used in the clinical setting.…”

Recommandations de bonne pratique clinique pour le suivi des patients neurologiques après injection de toxine botulique intradétrusorienne

“…The use of the same method of follow-up makes it difficult to identify the optimal parameters for administering botulinum A toxin intradetrusor injections. We here suggest the drafting of guidelines by a multidisciplinary team of French-speaking specialists in neuro-urology relative to neuro-urological Introduction Les injections de toxine botulique A (TBA) intradétruso-rienne se dessinent, aujourd'hui, comme un traitement de choix de l'hyperactivité vésicale et de l'hyperactivité du détrusor d'origine neurogène [1][2][3][4][5][6][7].…”